TY - JOUR
T1 - Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
T2 - Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
AU - Lebegge, Els
AU - Arnouk, Sana M
AU - Bardet, Pauline M R
AU - Kiss, Máté
AU - Raes, Geert
AU - Van Ginderachter, Jo A
N1 - Copyright © 2020 Lebegge, Arnouk, Bardet, Kiss, Raes and Van Ginderachter.
PY - 2020/7/9
Y1 - 2020/7/9
N2 - Over the past decade, cancer immunotherapy has been steering immune responses toward cancer cell eradication. However, these immunotherapeutic approaches are hampered by the tumor-promoting nature of myeloid cells, including monocytes, macrophages, and neutrophils. Despite the arsenal of defense strategies against foreign invaders, myeloid cells succumb to the instructions of an established tumor. Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation, antibody-dependent cell cytotoxicity and phagocytosis, actually seem to favor cancer progression. In this review, we discuss how rudimentary defense mechanisms deployed by myeloid cells can promote tumor progression.
AB - Over the past decade, cancer immunotherapy has been steering immune responses toward cancer cell eradication. However, these immunotherapeutic approaches are hampered by the tumor-promoting nature of myeloid cells, including monocytes, macrophages, and neutrophils. Despite the arsenal of defense strategies against foreign invaders, myeloid cells succumb to the instructions of an established tumor. Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation, antibody-dependent cell cytotoxicity and phagocytosis, actually seem to favor cancer progression. In this review, we discuss how rudimentary defense mechanisms deployed by myeloid cells can promote tumor progression.
UR - http://www.scopus.com/inward/record.url?scp=85088435969&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.01395
DO - 10.3389/fimmu.2020.01395
M3 - Scientific review
C2 - 32733461
VL - 11
SP - 1
EP - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
IS - 1395
M1 - 1395
ER -